Grupo 2: Oncología Médica Traslacional y Terapia Individualizada del Cáncer
Código de grupo: 6.02
Tipo de grupo: Consolidado
Descripción del grupo: Oncología médica traslacional y terapia individualizada del cáncer
Jefes de Grupo: Miguel Martín Jiménez
Integrantes del grupo | |
---|---|
Investigadores y personal de apoyo |
AGUADO | ORIHUELA | GEMA | |
AGUILAR | CABALLERO | IKER | |
ALAMEDA | GARCIA | IRENE | First Stage Researcher |
ALVA | BIANCHI | MANUEL | |
ALVAREZ | ALVAREZ | ROSA MARIA | Established Researcher |
ÁLVAREZ | CASTILLO | ENRIQUE LUIS | |
ARIAS | GARCIA | AINHOA | First Stage Researcher |
ARRANZ | ARIJA | JOSE ÁNGEL | Established Researcher |
ARREGUI | VALLES | MARTA | First Stage Researcher |
AYLLON | GARCIA | CAROLINA | First Stage Researcher |
BLANCO | VELILLA | ALBA | |
BUENO | ZAMORA | OSCAR | |
CALLES | BLANCO | ANTONIO | |
CALVO | FERRÁNDIZ | PILAR AITANA | |
CANTERO | MARTIN | MARTA | |
CAÑETE | GAMEZ | MARIA ISABEL | |
CARPEÑO | MARTIN-CARO | LAURA | |
CEBOLLERO | PRESMANES | MARÍA | |
CIUDAD | BABIANO | FRANCISCO | |
DE TOMÁS | PALACIOS | JORGE | |
DEL MONTE | MILLAN | MARIA | |
DELGADO | SALAS | GUADALUPE | |
ECHAVARRIA | DIAZ-GUARDAMINO | ISABEL | |
ESCOBAR | ALVAREZ | YOLANDA | |
ESTEBAN | ARRANZ | MAGDALENA | |
FERNANDEZ | GONZALEZ | SARA | |
FLORES | SANCHEZ | CARMEN | |
FLOREZ | PEÑASCO | SANDRA | |
FOX | ANZORENA | BÁRBARA | |
GALERA | LOPEZ | MARIA DEL MAR | |
GALINDO | BARREALES | FERNANDO | |
GARCIA | LABORDA | ELSA | |
GARCIA | HIDALGO | MARIA ELENA | |
GARCIA | MALDONADO | ANA | |
GARCIA | PARDO DE SANTAYANA | MIGUEL ÁNGEL | |
GARCIA | ALFONSO | MARÍA PILAR | |
GONZALEZ | BLAZQUEZ | MARÍA VICTORIA | |
GONZALEZ DEL VAL | SUBIRATS | RICARDO | |
GRAS | PERAL | INMACULADA CONCEPCION | |
GUTIERREZ | ALONSO | NATALIA | |
GUTIERREZ | ORTIZ DE LA TABLA | ANA | |
HERRERO | LOPEZ | BLANCA | |
ILAS | CLAUDIA | RENATA | |
IRUELA | DE PEDRO | MARIA ENCARNACION | |
JEREZ | GILARRANZ | YOLANDA | |
JIMENEZ | VICENTE | MERCEDES | |
JULIAO | CAMAÑO | DAVID SALOMÓN | |
KHOSRAVI | SHAHI | PARHAM | |
LLORCA | ESCRIVA | MIREIA | |
LOBATO | VIDAL | NEREA | |
LOPEZ | JUAREZ | ESTELA | |
LOPEZ | LOPEZ | CRISTINA | |
LOPEZ | JIMENEZ | CARLOS | |
LÓPEZ-TARRUELLA | COBO | SARA | |
LUQUE | MOLINA | MARIA SOLEDAD | |
MARQUEZ | RODAS | IVAN | |
MARTIN | ALONSO | ALHELIES | |
MARTIN | JIMENEZ | MIGUEL | Leading Researcher |
MARTINEZ | DELFRADE | IÑIGO | |
MARTINEZ | PEREZ | MONICA | |
MASSARRAH | SANCHEZ | TATIANA | |
MORON | GARCIA | BLANCA ISABEL | |
MUÑANA | VILLAR | ALBERTO | |
MUÑIZ | FRUTOS | SARA | |
MUÑOZ | MARTÍN | ANDRES | |
OCAÑA | TORRES | INMACULADA | |
OLCOZ | MONREAL | FRANCISCO JAVIER | |
ORTEGA | MORAN | LAURA | |
PALOMERO | PLAZA | MARIA ISABEL | |
PARRA | HERNANDEZ | IRENE | |
PEREZ | RAMIREZ | SARA | |
PEREZ | DE LA FUENTE | INES | |
PEREZ | MONTIJANO | MARTA | |
PICORNELL | COMPANY | ANTONIO CLEMENTE | |
PUENTE | VAZQUEZ | BEATRIZ | |
RAMOS | MEDINA | ROCIO | |
RANZ | HERRANZ | MARIA ISABEL | |
RINCÓN | OLBÉS | PATRICIA | |
ROCHE | MOLINA | MARTA | |
RODRIGUEZ | VILLAR | CRISTINA | |
ROMERO | PICAZO | PAULA | |
RUIZ | BOLAÑOS | ANA BELEN | |
SABIN | DOMINGUEZ | MARÍA PILAR | |
SANCHEZ | HERRERO | ROSA MARIA | |
SANDOVAL | GARCIA | CARMEN | |
SOTO | ALSAR | JAVIER | |
TALEGON | GARCIA | MARIA DEL PILAR | |
TIRADO | ANULA | VICTORIA CLARA | First Stage Researcher |
DE TORO | CARMENA | MARIA | First Stage Researcher |
TORRES | PEREZ-SOLERO | GABRIELA | First Stage Researcher |
TORVISCO | NAJARRO | JOSE MARIA | |
VARGAS | SANCHEZ | AROA | First Stage Researcher |
VILLAREJO | LOPEZ | LUCIA | First Stage Researcher |
ZAZO | LEON | MARIA TERESA | First Stage Researcher |
Líneas de investigación | |
---|---|
Axis 1: Scientific leadership, integration and organization.
L1: Value of liquid biopsy as a predictor of response in cancer patients. Axis 2: International relations, alliances and visibility. L1: Search for predictors of response to neoadjuvant chemotherapy with docetaxel carboplatin in patients with triple negative breast cancer. L2: Development of preclinical PDXs models. L3: Development of Organoids. L4: Development of new technologies with impact on the oncology patient (FAITH). Axis 3: Consolidation of innovation. L1: Oncological Genetic Counselling. Axis 4: Competitiveness (sustainability) and resources available for research. L1: Development of murine breast cancer Tumorgrafts. L2: Search for genomic profiles as predictors of response in oncology patient. Axis 5: Quality and management of research and innovation. L1: Immunotherapy for cancer disease L2: Innovation in treatment of colorectal cancer. L3: Innovation in treatment of gastric cancer. L4: Innovation in treatment of lung cancer. L5: Innovation in treatment of genitourinary tumours. L6: Innovation in systemic treatment of brain tumours. L7: Innovation in systemic treatment of melanoma. L8: Innovation in the diagnosis of patients with stage I-III breast cancer. L9: (Neo) adjuvant breast cancer chemotherapy |
First decile publications | 13 | 388,5 |
First quartile publications | 35 | 541,3 |
Second quartile publications | 18 | 85,4 |
Third quartile publications | 16 | 48,1 |
Total publications (including those without IF) | 81 | 678,7 |